Skip to main content

Table 3 Means QOL scores over time

From: Quality-of-life evaluation for advanced non-small-cell lung cancer: a comparison between vinorelbine plus gemcitabine followed by docetaxel versus paclitaxel plus carboplatin regimens in a randomized trial: Japan Multinational Trial Organization LC00-03 (BRI LC03-01)

  PC group (n = 34), mean (SD) VGD group (n = 34), mean (SD)
Assessment time Baseline 6 week 12 week 18 week Baseline 6 week 12 week 18 week
FACT-G         
   Physical well-being (7 items) 21.8 (5.3) 16.9 (7.1) 16.1 (5.4) 12.8 (5.7) 21.4 (5.3) 19.1 (6.7) 20.2 (6.2) 20.2 (5.1)
   Social/family well-being (7 items) 19.7 (4.7) 19.7 (5.0) 18.9 (6.2) 19.4 (5.2) 18.9 (6.0) 19.6 (4.9) 20.1 (5.1) 17.2 (6.0)
   Emotional well-being (6 items) 16.1 (5.1) 15.6 (5.9) 15.5 (6.4) 13.6 (5.6) 14.1 (5.8) 16.3 (5.5) 16.8 (5.1) 16.4 (5.5)
   Functional well-being (7 items) 17.5 (6.7) 14.9 (6.3) 15.2 (6.6) 13.1 (5.4) 16.2 (6.9) 17.2 (6.5) 19.2 (6.0) 16.4 (7.2)
   FACT-G total (27 items) 73.0 (15.4) 65.1 (17.5) 63.4 (17.4) 57.1 (14.7) 69.0 (12.8) 70.3 (16.7) 74.6 (15.7) 68.9 (16.5)
FACT-L         
   Lung cancer subscale (7 items) 19.0 (5.1) 19.3 (3.8) 19.3 (4.8) 18.8 (4.2) 18.9 (3.7) 18.9 (6.0) 20.3 (4.5) 20.4 (5.1)
   Trial outcome index-lung (21 items) 57.6 (12.5) 51.2 (13.3) 49.9 (13.8) 44.6 (10.6) 56.2 (10.8) 55.1 (15.9) 59.7 (14.2) 57.0 (14.8)
FACT-Taxane         
   Neurotoxicity (11 items) 40.3 (4.1) 30.0 (9.4) 24.3 (9.3) 16.0 (7.2) 39.6 (5.6) 37.4 (7.2) 38.9 (5.5) 37.0 (7.0)
   Taxane (16 items) 59.9 (4.3) 47.5 (12.0) 41.0 (11.7) 30.4 (9.9) 59.1 (6.8) 56.5 (8.9) 58.3 (6.1) 55.4 (9.3)
   Trial outcome index-taxane (30 items) 98.9 (13.7) 78.9 (21.2) 70.9 (17.4) 55.8 (15.9) 96.7 (11.9) 92.5 (18.0) 97.7 (15.1) 91.8 (16.8)
FACIT-Sp         
   Spirituality (12 items) 30.3 (9.8) 30.1 (9.6) 28.3 (11.8) 27.2 (12.4) 28.4 (11.5) 29.6 (9.8) 28.3 (11.4) 30.0 (9.4)